MNG221
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.344
- PANCREAS_BETA_CELLS+0.266
- NOTCH_SIGNALING+0.169
- HEDGEHOG_SIGNALING+0.159
- ANGIOGENESIS+0.157
- BILE_ACID_METABOLISM+0.136
- ESTROGEN_RESPONSE_LATE+0.104
- APICAL_SURFACE+0.095
- ESTROGEN_RESPONSE_EARLY+0.056
- MYOGENESIS+0.027
Top 10 suppressed
- MYC_TARGETS_V1-0.560
- UNFOLDED_PROTEIN_RESPONSE-0.513
- TGF_BETA_SIGNALING-0.510
- TNFA_SIGNALING_VIA_NFKB-0.494
- DNA_REPAIR-0.477
- PROTEIN_SECRETION-0.476
- IL6_JAK_STAT3_SIGNALING-0.454
- MTORC1_SIGNALING-0.407
- INTERFERON_ALPHA_RESPONSE-0.379
- INTERFERON_GAMMA_RESPONSE-0.373
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1337909 | GTEX | — | 0.903 |
| 2 | SRR1388378 | GTEX | — | 0.900 |
| 3 | SRR1477080 | GTEX | — | 0.900 |
| 4 | SRR33346947 | — | — | 0.898 |
| 5 | BS_JXNZYGCR | DNET | — | 0.892 |
| 6 | MNG491 | — | — | 0.891 |
| 7 | SJEPD001526_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.891 |
| 8 | SRR1500868 | GTEX | — | 0.890 |
| 9 | BS_9RT63JD9 | low-grade glioma | — | 0.888 |
| 10 | MNG1044 | — | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.344 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.266 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.169 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.159 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.157 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.136 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.104 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.095 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.056 | Inavolisib | — uncovered |
| MYOGENESIS | 0.027 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.027 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.023 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.013 | Remibrutinib | — uncovered |
| COAGULATION | 0.005 | Binimetinib | — uncovered |